Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Habibian · SciRah

Researcher profile · Semantic Scholar

M. Habibian

Share profile

M. Habibian — researcher profile on SciRah

h-index: 17
Works: 53
Citations: 2,742

Most-cited papers

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
G. Gravis, K. Fizazi, F. Joly, S. Oudard +29 more
2013The Lancet Oncology635 citations
Semantic Scholar
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
G. Gravis, J. Boher, F. Joly, M. Soulie +16 more
2016European Urology429 citations
Semantic Scholar
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
C. Carrie, A. Hasbini, G. de Laroche, P. Richaud +18 more
2016The Lancet Oncology369 citations
Semantic Scholar
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies
G. Gravis, J. Boher, Yu-Hui Chen, Glenn Liu +16 more
2018European Urology236 citations Open access
Semantic Scholar
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
K. Fizazi, L. Faivre, F. Lesaunier, R. Delva +27 more
2015The Lancet Oncology219 citations
Semantic Scholar
Personalised chemotherapy based on tumour marker decline in poor-prognosis germ-cell tumours: results of the GETUG 13 phase III trial
K. Fizazi, L. Pagliaro, A. Laplanche, A. Flechon +18 more
2014The Lancet Oncology171 citations Open access
Semantic Scholar
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
G. Gravis, J. Boher, K. Fizazi, F. Joly +31 more
2015European Urology124 citations Open access
Semantic Scholar
Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).
G. Gravis, P. Marino, F. Joly, S. Oudard +30 more
2014European Journal of Cancer68 citations
Semantic Scholar
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
P. Lavaud, G. Gravis, S. Foulon, F. Joly +34 more
2017European Urology64 citations
Semantic Scholar
Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial.
G. Gravis, J. Boher, F. Joly, S. Oudard +16 more
201552 citations
Semantic Scholar
Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediary analysis of GETUG 14 randomized trial (EU-20503/NCT00104741).
B. Dubray, V. Beckendorf, S. Guérif, E. le Prisé +14 more
2011Journal of Clinical Oncology49 citations
Semantic Scholar
Definition of lymph node areas for radiotherapy of prostate cancer: A critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU).
P. Sargos, S. Guérif, I. Latorzeff, C. Hennequin +10 more
2015Cancer Treatment Reviews46 citations
Semantic Scholar
A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13.
K. Fizazi, L. Pagliaro, A. Flechon, J. Mardiak +16 more
2013Journal of Clinical Oncology32 citations
Semantic Scholar
Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial.
P. Blanchard, L. Faivre, F. Lesaunier, N. Salem +16 more
2016International Journal of Radiation Oncology, Biology, Physics29 citations
Semantic Scholar
Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.
Y. Loriot, L. Pagliaro, A. Flechon, J. Mardiak +20 more
2017European Journal of Cancer22 citations
Semantic Scholar
Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naïve Prostate Cancer.
C. Schuurhuizen, P. Marino, A. Braamse, L. Buffart +10 more
2018The Journal of the National Comprehensive Cancer Network18 citations Open access
Semantic Scholar
Mature results of the GETUG 13 phase III trial in poor-prognosis germ-cell tumors (GCT).
K. Fizazi, A. Flechon, G. Le Teuff, J. Mardiak +16 more
201618 citations
Semantic Scholar
Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC) and brain metastases: Preliminary results from the GETUG-AFU 26 (Nivoren) study.
B. Escudier, S. Chabaud, D. Borchiellini, G. Gravis +10 more
201715 citations
Semantic Scholar
Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for biological relapse (BR) after radical prostatectomy (RP): Results of the GETUG-AFU 16 phase III randomized trial—NCT00423475.
C. Carrie, A. Hasbini, G. de Laroche, M. Habibian +16 more
201515 citations
Semantic Scholar
Docetaxel-estramustine in localized high-risk prostate cancer: Results of the French Genitourinary Tumor Group GETUG 12 phase III trial.
K. Fizazi, A. Laplanche, F. Lesaunier, R. Delva +16 more
201411 citations
Semantic Scholar
[A randomized controlled trial of metastases-directed treatment in patients with metastatic prostate cancer using stereotactic body irradiation: A GETUG-AFU trial].
P. Blanchard, S. Foulon, G. Louvel, M. Habibian +1 more
2017Cancer Radiothérapie10 citations
Semantic Scholar
Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP)
Wan-Ling Xie, C. Sweeney, M. Regan, M. Nakabayashi +15 more
201610 citations Open access
Semantic Scholar
Docetaxel-estramustine in high-risk localized prostate cancer: First results of the French Genitourinary Tumor Group phase III trial (GETUG 12).
K. Fizazi, F. Lesaunier, R. Delva, G. Gravis +16 more
2011Journal of Clinical Oncology10 citations
Semantic Scholar
Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial.
P. Marino, P. Sfumato, F. Joly, K. Fizazi +5 more
2017European Journal of Cancer8 citations
Semantic Scholar
The benefit of combining docetaxel to androgen deprivation therapy in localized and metastatic castration-sensitive prostate cancer as predicted by ERG status: An analysis of two GETUG phase III trials.
S. Rajpar, A. Carmel, Zahira Merabet, P. Vielh +16 more
20178 citations
Semantic Scholar
Burden of metastatic hormone-sensitive prostate cancer to identify men more likely to benefit from early docetaxel.
G. Gravis, J. Boher, Yu-Hui Chen, Glenn Liu +16 more
20177 citations
Semantic Scholar
Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP)
C. Sweeney, Wan-Ling Xie, M. Regan, M. Nakabayashi +15 more
20166 citations Open access
Semantic Scholar
A randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse.
K. Fizazi, M. Habibian, A. Laplanche, H. Baumert +3 more
20146 citations
Semantic Scholar
Efficacy and tolerance of treatments received beyond progression in men with metastatic hormone-naive prostate cancer treated with androgen deprivation therapy (ADT) with or without docetaxel in the GETUG-AFU 15 phase III trial.
P. Lavaud, G. Gravis, Clémence Legoupil, F. Joly +16 more
20165 citations
Semantic Scholar
A study of ERG, PTEN, and ki-67 in a phase III trial assessing docetaxel and estramustine in high-risk localized prostate cancer (GETUG 12).
S. Rajpar, P. Vielh, A. Laplanche, F. Lesaunier +16 more
20145 citations
Semantic Scholar
PSA response and early PSA progression evaluated in patients randomized in a phase III trial comparing androgen-deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naive metastatic prostate cancer (GETUG-AFU 15/0403).
G. Gravis, K. Fizazi, Florence Joly, S. Oudard +6 more
2011Journal of Clinical Oncology5 citations
Semantic Scholar
The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials.
S. Rajpar, Tony Ibrahim, A. Carmel, Zahira Merabet +17 more
2024European Urology Oncology4 citations
Semantic Scholar
Randomized Phase 3 Trial of Dose Escalation (80 vs 70 Gy) in High-Risk Prostate Cancers Combined With Long-term Androgen Deprivation: GETUG-AFU 18 Trial, Acute and 1-Year Toxicities
C. Hennequin, P. Richaud, L. Roca, Marlon Silva +13 more
20154 citations Open access
Semantic Scholar
A phase III randomized, open-label multicenter trial to evaluate the benefit of leuprorelin acetate for 24 months after radical prostatectomy in patients with high risk of recurrence (AFU-GETUG 20/0310).
F. Rozet, M. Habibian, J. Bérille, L. Roca +3 more
2012Journal of Clinical Oncology4 citations
Semantic Scholar
Genitourinary tumors, prostate
G. Gravis, K. Fizazi, F. J. Lobbedez, S. Oudard +16 more
20124 citations Open access
Semantic Scholar
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
S. Culine, A. Flechon, G. Gravis, G. Roubaud +19 more
2021Clinical Genitourinary Cancer2 citations Open access
Semantic Scholar
Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma: Final Results of the European Groupe d'Etude des Tumeurs Uro-Génitales (GETUG-01) Randomized Study
P. Pommier, S. Chabaud, Lagrange Jl, P. Richaud +9 more
20152 citations Open access
Semantic Scholar
Validation of a prognostic classification system for mediastinal nonseminomatous germ-cell tumors (MGCT).
L. Pagliaro, A. Laplanche, A. Flechon, J. Mardiak +16 more
20142 citations
Semantic Scholar
Identification of prognostic groups in patients with hormone-sensitive metastatic prostate cancer at the present time: An analysis of the GETUG 15 phase III trial.
G. Gravis, K. Fizazi, F. Joly, S. Oudard +16 more
2013Journal of Clinical Oncology2 citations
Semantic Scholar
Patients' self-assessment of tolerance and quality of life during docetaxel-based chemotherapy: Results from a phase III trial in hormone-naive metastatic prostate cancer patients (GETUG-AFU 15/0403).
Florence Joly, G. Gravis, S. Oudard, M. Soulie +6 more
20102 citations
Semantic Scholar
Safety results of a phase III trial evaluating ADT+ docetaxel versus ADT alone in hormone-naive metastatic prostate cancer patients (GETUG-AFU 15/0403).
I. Latorzeff, B. Esterni, M. Habibian, G. Delplanque +6 more
20102 citations
Semantic Scholar
Results of the GETUG-AFU 19 trial: A randomized phase II study of dose dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) with or without anti-epidermal growth factor receptor (EGF-R) monoclonal antibody panitumumab (PANI) in advanced transitional cell carcinoma (ATCC).
S. Culine, A. Flechon, G. Gravis, G. Roubaud +16 more
20171 citations
Semantic Scholar
How should we treat castration-resistant prostate cancer patients who have received androgen deprivation therapy (ADT) plus docetaxel upfront for hormone-sensitive diseae? Mature analysis of the GETUG-AFU 15 phase III trial
P. Lavaud, G. Gravis, Clémence Legoupil, S. Foulon +16 more
20161 citations Open access
Semantic Scholar
2554 Clinical outcome of initially metastatic hormone sensitive prostate cancer (HSPC) in real life population from a single center: Comparison with initially metastatic HSPC patients included in the GETUG-AFU 15 trial
M. Guérin, P. Sfumato, J. Boher, N. Salem +9 more
20151 citations
Semantic Scholar
Chiaroscuro hematopoietic stem cell.
P. Quesenberry, M. Habibian, Mark S. Dooner, S. Zhong +8 more
1998Transactions of the American Clinical and Climatological Association1 citations
Semantic Scholar
Tu1854 – Association Between Qpcr Assays Targeting Fims/Fimh and Aggregation to Eb8018 : Results of the Mobidic Study (Molecular Biomarkers and Adherent and Invasive Escherichia COLI (AIEC) Detection Study in Crohn's Disease Patients)
J. Paillarse, C. Bonny, M. Habibian, J. Plassais +3 more
2019Gastroenterology0 citations Open access
Semantic Scholar
Modelling relapse in patients with high-risk localised prostate cancer treated randomly in the GETUG 12 phase III trial reveals two populations of relapsing patients
Cecile Vicier, L. Faivre, F. Lesaunier, R. Delva +16 more
20160 citations Open access
Semantic Scholar
Disease burden and outcome in metastatic hormone sensitive prostate cancer (mHSPC).
L. Albiges, Wan-Ling Xie, Yu-Hui Chen, J. Boher +13 more
20150 citations
Semantic Scholar
PD-0046: Outcome according to pelvic radiotherapy in the GETUG 12 phase III trial for high-risk localized prostate cancer
P. Blanchard, L. Faivre, F. Lesaunier, N. Salem +6 more
20150 citations Open access
Semantic Scholar
Patterns of relapse in poor-prognosis germ cell tumors in the GETUG 13 trial: Implications for assessment of brain progression.
Y. Loriot, L. Pagliaro, A. Flechon, J. Mardiak +16 more
20140 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Gravis×34
Invite
G. Gravis — researcher profile on SciRah
K. Fizazi×32
Invite
K. Fizazi — researcher profile on SciRah
F. Rolland×25
Invite
F. Rolland — researcher profile on SciRah
R. Delva×24
Invite
R. Delva — researcher profile on SciRah

×19

Invite

C. Théodore — researcher profile on SciRah

Invite

S. Oudard — researcher profile on SciRah

Invite

L. Mourey — researcher profile on SciRah

Invite

S. Culine — researcher profile on SciRah

I. Latorzeff×17

Invite

I. Latorzeff — researcher profile on SciRah

I. Krakowski×17

Invite

I. Krakowski — researcher profile on SciRah

Invite

J. Ferrero — researcher profile on SciRah

Invite

M. Soulie — researcher profile on SciRah